2023
SAT-283 Intrahepatic cholangiocarcinoma developing in patients with metabolic syndrome is characterized by Osteopontin overexpression in the tumor stroma
Cadamuro M, Sarcognato S, Camerotto R, Girardi N, Lasagni A, Zanus G, Cillo U, Gringeri E, Morana G, Strazzabosco M, Campello E, Simioni P, Guido M, Fabris L. SAT-283 Intrahepatic cholangiocarcinoma developing in patients with metabolic syndrome is characterized by Osteopontin overexpression in the tumor stroma. Journal Of Hepatology 2023, 78: s564-s565. DOI: 10.1016/s0168-8278(23)01358-2.Peer-Reviewed Original ResearchIntrahepatic Cholangiocarcinoma Developing in Patients with Metabolic Syndrome Is Characterized by Osteopontin Overexpression in the Tumor Stroma
Cadamuro M, Sarcognato S, Camerotto R, Girardi N, Lasagni A, Zanus G, Cillo U, Gringeri E, Morana G, Strazzabosco M, Campello E, Simioni P, Guido M, Fabris L. Intrahepatic Cholangiocarcinoma Developing in Patients with Metabolic Syndrome Is Characterized by Osteopontin Overexpression in the Tumor Stroma. International Journal Of Molecular Sciences 2023, 24: 4748. PMID: 36902188, PMCID: PMC10003180, DOI: 10.3390/ijms24054748.Peer-Reviewed Original ResearchConceptsMetS patientsMetabolic syndromeNon-alcoholic fatty liver disease/non-alcoholic steatohepatitisNon-alcoholic steatohepatitisIntrahepatic cholangiocarcinoma developmentPutative therapeutic targetDeposition of osteopontinCell-like phenotypeBiliary tumorigenesisExtracellular matrix depositionVascular complicationsSurgical resectionIntrahepatic cholangiocarcinomaICCA cellsOverexpression of osteopontinPredictive biomarkersLiver tumorsCommon conditionHuCCT-1Tumor stromaCholangiocarcinoma developmentPeritumoral areaTherapeutic targetBiliary differentiationOsteopontin overexpression
2022
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook
Jaffe A, Taddei TH, Giannini EG, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver International 2022, 42: 2607-2619. PMID: 36161463, PMCID: PMC10878125, DOI: 10.1111/liv.15432.Peer-Reviewed Original ResearchConceptsLiver diseaseHepatocellular carcinomaLiver functionRisk factorsRelevant prognostic roleChronic hepatitis BResidual liver functionChronic liver diseaseManagement of patientsCare of patientsCommon risk factorsAppropriate surveillance strategiesSuccessful cancer treatmentC infectionCommon complicationHepatitis BMetabolic syndromePrognostic roleSignificant morbidityLongitudinal careCurrent careCancer recurrenceHCC managementLiver cancerHCC treatmentMetabolic Syndrome and Liver Cancer
Jaffe A, Strazzabosco M. Metabolic Syndrome and Liver Cancer. 2022, 87-104. DOI: 10.1007/978-3-030-41683-6_51.Peer-Reviewed Original ResearchHepatitis B virusNonalcoholic fatty liver diseaseMetabolic syndromeRisk factorsHepatocellular carcinomaLiver diseaseLiver cancerParticular hepatitis B virusIncidence of HCCAdvanced liver diseaseIndependent risk factorFatty liver diseaseType 2 diabetesUnderlying pathogenic mechanismsHepatic manifestationHCC incidenceViral hepatitisAdvanced fibrosisSignificant morbidityDiabetes leadsTime patientsB virusHCC riskHigh prevalenceLower incidenceInflammatory pathways and cholangiocarcioma risk mechanisms and prevention
Cadamuro M, Strazzabosco M. Inflammatory pathways and cholangiocarcioma risk mechanisms and prevention. Advances In Cancer Research 2022, 156: 39-73. PMID: 35961707, PMCID: PMC10916841, DOI: 10.1016/bs.acr.2022.02.001.Peer-Reviewed Original ResearchConceptsDevelopment of cholangiocarcinomaNonalcoholic fatty liver diseaseAdequate therapeutic treatmentPrimary sclerosing cholangitisFatty liver diseasePro-inflammatory mechanismsMain risk factorsProdromal diseaseSclerosing cholangitisCaroli's diseaseMetabolic syndromeChronic cholangiopathiesLiver diseasePoor prognosisInflammatory pathwaysBiliary treeCCA developmentRisk factorsImmune responseImmunological responseTherapeutic targetCholangiocarcinomaFluke infestationRole of cellExtrahepatic areas
2021
The Neglected Role of Bile Duct Epithelial Cells in NASH
Cadamuro M, Lasagni A, Sarcognato S, Guido M, Fabris R, Strazzabosco M, Strain AJ, Simioni P, Villa E, Fabris L. The Neglected Role of Bile Duct Epithelial Cells in NASH. Seminars In Liver Disease 2021, 42: 034-047. PMID: 34794182, DOI: 10.1055/s-0041-1739455.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseNonalcoholic steatohepatitisLiver diseaseInsulin resistancePrevalent liver diseaseBile duct epithelial cellsFatty liver diseaseSubset of patientsCommon pathogenetic mechanismDuct epithelial cellsMultiple biological effectsFibro-inflammationHepatic manifestationNAFLD patientsPortal fibrosisMetabolic syndromeBile ductDuctular reactionDisease progressionPathogenetic mechanismsLiver cancerMetabolic alterationsProgenitor cell compartmentEpithelial cellsDiseaseMetabolic Syndrome and Liver Cancer
Jaffe A, Strazzabosco M. Metabolic Syndrome and Liver Cancer. 2021, 1-19. DOI: 10.1007/978-3-030-37482-2_51-1.Peer-Reviewed Original ResearchHepatitis B virusNonalcoholic fatty liver diseaseMetabolic syndromeRisk factorsHepatocellular carcinomaLiver diseaseLiver cancerParticular hepatitis B virusIncidence of HCCAdvanced liver diseaseIndependent risk factorFatty liver diseaseType 2 diabetesUnderlying pathogenic mechanismsHepatic manifestationHCC incidenceViral hepatitisAdvanced fibrosisSignificant morbidityDiabetes leadsTime patientsB virusHCC riskHigh prevalenceLower incidence